Telix Pharmaceuticals Limited Surges After Upgrading FY25 Revenue Guidance

Highlights:

• Shares of Telix Pharmaceuticals Limited (ASX: TLX) surged 16.3% to A$16.70 at the time of writing after the company raised its FY25 revenue guidance.
• The biotech now expects to generate US$800–US$820 million in revenue, up from its previous forecast of US$770–US$800 million.
• Strong Q3 results, driven by sales of Illuccix® and Gozellix® and new U.S. reimbursement approvals, boosted investor confidence.

Telix Pharmaceuticals Limited (ASX: TLX) saw its shares soar by 16.3 per cent to A$16.70 at the time of writing, after the biotech company raised its full-year 2025 revenue guidance late on Tuesday. The company now expects to generate between US$800 million and US$820 million in revenue for FY25, reflecting stronger-than-anticipated commercial performance.

Strong Quarterly Results Boost Confidence

In the third quarter ending 30 September, Telix reported unaudited group revenue of around US$206 million, representing a 53 per cent year-on-year increase. The company credited the surge to robust sales of its PSMA imaging products, Illuccix® and Gozellix®, along with contributions from its radiopharmacy services business. A significant catalyst for growth came from the U.S. Centers for Medicare & Medicaid Services (CMS), which recently granted Transitional Pass-Through (TPT) payment status and a dedicated billing code for Gozellix®. This move is expected to enhance reimbursement access and accelerate adoption across U.S. diagnostic imaging facilities.

Upgraded Outlook Reflects Strong Momentum

Telix previously projected FY25 revenue in the range of US$770 million to US$800 million, but has now lifted its forecast to US$800 million–US$820 million. The upgrade signals increasing confidence in sustained growth across its diagnostic and therapeutic divisions, supported by expanding global distribution and favorable reimbursement trends. The company also reaffirmed its commitment to ongoing investment in research & development, emphasizing its plans to advance its radiopharmaceutical pipeline while scaling operations internationally.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com